ICON Public Limited Company (ICLR) Stock

About ICON Public Limited Company

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

ICON Public Limited Company is led by CEO Barry Balfe, employs 40,100 people, headquartered in Dublin, IE, publicly traded since 1998.

ICON Public Limited Company (ICLR) stock trades at $180.00 with a market capitalization of $13.78B. The stock is valued at a price-to-earnings (P/E) ratio of 11.92, price-to-book of 0.91, price-to-sales of 1.07. Over the past 52 weeks the stock has ranged between $66.57 and $211.00, and currently trades 14.7% below its 52-week high.

On profitability, ICON Public Limited Company generates a return on equity (ROE) of 8.31%, return on capital employed of 11.53%, an operating margin of 13.26%, a net profit margin of 7.40%.

Official website: www.iconplc.com